A Phase 1 interventional study of Repaglinide and Pirtobrutinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) in adult healthy participants. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). The study is conducted in two periods. Participants will stay in this study for up to 54 days.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 0.5 milligrams (mg) repaglinide tablet, in the morning on Day 1.
Drug: Repaglinide
Participants received oral doses of 200 mg pirtobrutinib tablets, once daily (QD) in the morning from Day 2 to Day 11.
Drug: Pirtobrutinib
Participants received oral doses of 200 mg pirtobrutinib QD and 0.5 mg repaglinide tablets, in the morning on Day 12.
Drug: Repaglinide · Drug: Pirtobrutinib
Administered orally.
Administered orally.
Also known as: LOXO-305, LY3527727
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide
PK: AUC(0-t) of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide
PK: AUC(0-inf) of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide
PK: AUC-inf (%extrap) of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Maximum Observed Concentration (Cmax) of Repaglinide
PK: Cmax of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Repaglinide
PK: Tmax of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Apparent Terminal Elimination Rate Constant (Lambda Z) of Repaglinide
PK: Lambda Z of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Apparent Systemic Clearance (CL/F) of Repaglinide
PK: CL/F of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Repaglinide
PK: t½ of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Apparent Volume of Distribution (Vz/F) of Repaglinide
PK: Vz/F of repaglinide was reported.
Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
PK: AUC0-t of pirtobrutinib was reported.
Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib
PK: AUCtau of pirtobrutinib was reported.
Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib
PK: Cmax of pirtobrutinib was reported.
Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
PK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Pirtobrutinib
PK: Ctrough of pirtobrutinib was reported.
Time frame: Period 2: 24-hour post-dose on Day 12
PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
PK: Tmax of pirtobrutinib was reported.
Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
PK: Apparent Systemic Clearance (CL/F) at Steady State of Pirtobrutinib
PK: CL/F at steady state of pirtobrutinib was reported.
Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
| Milestone | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|---|
| Started | 16 | 0 | 0 |
| Completed | 16 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|---|
| Started | 16 | 0 | 0 |
| Completed | 16 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|---|
| Started | 0 | 16 | 0 |
| Completed | 0 | 16 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|---|
| Started | 0 | 0 | 16 |
| Completed | 0 | 0 | 16 |
| Not completed | 0 | 0 | 0 |
PK: AUC(0-t) of repaglinide was reported.
| hour*nanogram per milliliter (h*ng/mL) | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide | 9.59 ± 36.9 | 22.2 ± 56.1 |
PK: AUC(0-inf) of repaglinide was reported.
| h*ng/mL | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide | 9.79 ± 36.5 | 22.5 ± 55.7 |
PK: AUC-inf (%extrap) of repaglinide was reported.
| percentage of AUC0-inf extrapolated | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide | 1.94 ± 41.8 | 1.10 ± 60.6 |
PK: Cmax of repaglinide was reported.
| nanogram per milliliter (ng/mL) | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Repaglinide | 6.88 ± 59.3 | 13.6 ± 47.4 |
PK: Tmax of repaglinide was reported.
| hour | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Repaglinide | 0.625 (0.333 to 1.00) | 0.750 (0.500 to 1.00) |
PK: Lambda Z of repaglinide was reported.
| one per hour (1/h) | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| Participant 1 | 0.128 | 0.152 |
| Participant 2 | 0.130 | 0.150 |
| Participant 3 | 0.228 | 0.151 |
| Participant 4 | 0.0847 | 0.157 |
| Participant 5 | 0.0809 | 0.139 |
| Participant 6 | 0.126 | 0.141 |
| Participant 7 | 0.138 | 0.247 |
| Participant 8 | 0.219 | 0.0995 |
| Participant 9 | 0.183 | 0.208 |
| Participant 10 | 0.197 | 0.218 |
| Participant 11 | 0.147 | 0.118 |
| Participant 12 | 0.139 | 0.174 |
| Participant 13 | 0.181 | 0.148 |
| Participant 14 | 0.105 | 0.170 |
| Participant 15 | 0.221 | 0.220 |
| Participant 16 | 0.0966 | 0.325 |
PK: CL/F of repaglinide was reported.
| Liter per hour (L/h) | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Repaglinide | 51.1 ± 36.5 | 22.2 ± 55.7 |
PK: t½ of repaglinide was reported.
| hour | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| PK: Apparent Plasma Terminal Elimination Half-life (t½) of Repaglinide | 4.86 ± 34.6 | 4.11 ± 30.0 |
PK: Vz/F of repaglinide was reported.
| Liter | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|
| PK: Apparent Volume of Distribution (Vz/F) of Repaglinide | 358 ± 39.3 | 131 ± 66.0 |
PK: AUC0-t of pirtobrutinib was reported.
| h*ng/mL | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib | 184000 ± 22.1 |
PK: AUCtau of pirtobrutinib was reported.
| h*ng/mL | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|
| PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib | 105000 ± 18.0 |
PK: Cmax of pirtobrutinib was reported.
| ng/mL | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|
| PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib | 7220 ± 15.0 |
PK: Ctrough of pirtobrutinib was reported.
| ng/mL | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|
| PK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Pirtobrutinib | 3050 ± 21.8 |
PK: Tmax of pirtobrutinib was reported.
| hour | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|
| PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib | 1.00 (0.500 to 5.00) |
PK: CL/F at steady state of pirtobrutinib was reported.
| Liter per hour (L/h) | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|
| PK: Apparent Systemic Clearance (CL/F) at Steady State of Pirtobrutinib | 1.91 ± 18.0 |
Collected over Baseline up to 23 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: 0.5 mg Repaglinide | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Period 2: 200 mg Pirtobrutinib QD | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Event | Period 1: 0.5 mg Repaglinide | Period 2: 200 mg Pirtobrutinib QD | Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide |
|---|---|---|---|
| PetechiaeSkin and subcutaneous tissue disorders | 0/16 | 4/16 | 0/16 |
| Abdominal pain upperGastrointestinal disorders | 0/16 | 1/16 | 0/16 |
| ConstipationGastrointestinal disorders | 0/16 | 1/16 | 0/16 |
| NauseaGastrointestinal disorders | 1/16 | 0/16 | 0/16 |
| Feeling abnormalGeneral disorders | 0/16 | 1/16 | 0/16 |
| Back painMusculoskeletal and connective tissue disorders | 1/16 | 0/16 | 0/16 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/16 | 1/16 | 0/16 |
| AcneSkin and subcutaneous tissue disorders | 0/16 | 0/16 | 1/16 |
All enrolled participants.
| Age, Continuous(years) | Period 1: 0.5 mg Repaglinide |
|---|---|
| Mean | 39.1 ± 9.20 |
| Sex: Female, Male(Participants) | Period 1: 0.5 mg Repaglinide |
|---|---|
| Female | 5 |
| Male | 11 |
| Ethnicity (NIH/OMB)(Participants) | Period 1: 0.5 mg Repaglinide |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Period 1: 0.5 mg Repaglinide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 13 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Period 1: 0.5 mg Repaglinide |
|---|---|
| United States | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Dec 2020, 1 month.
Results were first posted in Mar 2025, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Repaglinide · Pirtobrutinib